Applications of 5-Chloro-1-Methyl-3-(Trifluoromethyl)-1H-Pyrazole-4-Carboxylic Acid in Industrial Manufacturing

As the original manufacturer, we supply 5-Chloro-1-Methyl-3-(Trifluoromethyl)-1H-Pyrazole-4-Carboxylic Acid for critical processes across several advanced chemical industries. Our expertise supports downstream customers in key sectors where this intermediate enables unique functionality, regulatory compliance, and process efficiency.

1. Agrochemical Active Ingredient Synthesis

Formulators in the crop protection sector use this intermediate to construct pyrazole-based frameworks present in selective herbicides and fungicides. The compound reacts well in cyclization and acylation steps critical for structurally complex actives, offering improved yield and lower impurity profiles compared to less selective starting materials. Process engineers target high purity levels to meet the regulatory thresholds on trace residuals in finished products, with analytical controls enforced at both intermediate and final stages.

Industry compliance standards

• FAO/WHO Specification for Pesticide Active Ingredients
• EU Regulation (EC) No 1107/2009 on Plant Protection Products
• REACH registration as an industrial intermediate
• ISO 9001-based Quality Management during synthesis and QC

Typical usage ratio

• 8-25% of total raw input by mass, adjusted based on targeted molecule design and overall batch yield optimization

Downstream process integration

• Feeds into condensation or cyclization as a principal core-building block after primary nitration and halogenation steps
• Followed by further functional group modification or protection, leading to purification and formulation

Final product types

• Pre-emergence herbicides for cereals and maize
• Triazole-based fungicides for fruits and vegetables

2. Pharmaceutical Intermediate Manufacturing

Pharmaceutical innovator and generic manufacturers select this pyrazolecarboxylic acid as a core building block for APIs incorporating trifluoromethylated heterocycles, prized for increased metabolic stability and receptor specificity. Controlled crystal morphology and impurity control help downstream processors achieve stringent specification requirements for regulated markets. The intermediate frequently enters amidation, esterification, or halogen exchange reactions that define final pharmacological behavior.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredient Manufacturing
• USP/NF and Ph.Eur. Monograph Guidance for Intermediates
• 21 CFR Part 211 (USFDA cGMP)
• EDQM Certificate of Suitability where applicable

Typical usage ratio

• 5-18% w/w in the synthesis route, tailored according to API scaffold and number of downstream modifications

Downstream process integration

• Introduced post-halogenation in the heterocycle assembly section
• Directly coupled to amines or alcohols under controlled temperature, followed by multi-step purification

Final product types

• Anti-inflammatory and CNS drug intermediates
• Fluorinated lead candidates in oncology and anti-viral therapies

3. Specialty Fine Chemical Synthesis

Producers of high-value fine chemicals use this material in the stepwise construction of trifluoromethylated heterocycles, essential to UV absorbers, advanced organic photoactive compounds, and catalytic ligands. Its well-defined reactivity provides chemists flexibility when designing regiospecific syntheses, especially in custom contract manufacturing settings for electronics and materials applications. Tight in-process control is maintained with real-time HPLC and NMR monitoring to minimize by-products and maximize process throughput.

Industry compliance standards

• ISO 9001:2015 for chemical synthesis
• REACH Annex VI requirements for European supply
• TSCA Inventory Listing for US production and downstream import
• Custom specification agreements for purity, heavy metals, and trace solvents

Typical usage ratio

• 12-30% of reaction mass, optimized based on final molecule complexity and purity requirements

Downstream process integration

• Core intermediate for organofluorine coupling reactions post-chlorination
• Carboxyl group activated for subsequent esterification or amidation en route to end use molecules

Final product types

• UV-blocking agents for advanced coatings
• Photoresist materials for microelectronics
• Ligands for homogeneous catalysis in olefin polymerization

4. Veterinary Drug Intermediate Production

Manufacturers serving the animal health sector utilize this compound in the construction of novel veterinary APIs, particularly where metabolic resistance and environmental degradation profiles demand a fluorinated heterocycle core. The strict specification on residual chlorinated pyrazoles and solvent traces responds to international veterinary pharmacopeial regulations, while batch traceability supports large-scale GMP batch recordkeeping. It enables consistent API quality, meeting the needs of both formulation and registration work.

Industry compliance standards

• VICH GL GMP for Veterinary Active Pharmaceutical Ingredients
• European Pharmacopoeia standards for veterinary actives
• US FDA Guidance for Industry (GFI) 152 for animal drugs
• Good Laboratory Practice (GLP) for preclinical lot processing

Typical usage ratio

• 8-22% by initial molar input, adjusted for final API dosage strength and formulation platform

Downstream process integration

• Intermediate for coupling to alkyl amines or etherification steps in veterinary synthetic route
• Feeds directly into API crystallization and micronization prior to formulation

Final product types

• Anti-parasitic agents for livestock
• Fluorinated anti-inflammatory veterinary drugs
• Feed additive actives for poultry industry